Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Upacicalcet - EA Pharma/JW Pharmaceutical/Pathalys Pharma/Sanwa Kagaku Kenkyusho/Tasly Pharmaceutical Group

Drug Profile

Upacicalcet - EA Pharma/JW Pharmaceutical/Pathalys Pharma/Sanwa Kagaku Kenkyusho/Tasly Pharmaceutical Group

Alternative Names: AJT-240; PLS-240; SK-1403; Upacicalcet sodium hydrate; UPASITA

Latest Information Update: 08 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ajinomoto Pharma
  • Developer Launch Therapeutics; Pathalys Pharma; Sanwa Kagaku Kenkyusho
  • Class Amides; Amines; Antianaemics; Chlorobenzenes; Propionic acids; Small molecules; Sulfonic acids; Toluenes
  • Mechanism of Action Calcium-sensing receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Secondary hyperparathyroidism
  • Phase III Anaemia

Most Recent Events

  • 15 May 2023 Pathalys Pharma in collaboration with Launch Therapeutics initiates phase-III PATH-2 trial in Secondary hyperparathyroidism in USA (IV) (EudraCT2023-504339-41) (NCT05836220) (PP3003)
  • 09 May 2023 Pathalys Pharma plans a phase III trial (PATH-2) for Secondary Hyperparathyroidism (IV) by May 2023 (NCT05836220) (EudraCT2023-504339-41)
  • 28 Apr 2023 Phase-III clinical trials in Secondary hyperparathyroidism in USA (IV) (NCT05832931) (EudraCT2023-504338-24)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top